Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon‐like peptide‐1 receptor agonists-Reference-Cited by-同舟云学术

Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon‐like peptide‐1 receptor agonists

Published:2020-02-06 Issue:5 Volume:22 Page:817-827
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Sciannameo Veronica¹,Berchialla Paola²,Orsi Emanuela³,Lamacchia Olga⁴,Morano Susanna⁵,Querci Fabrizio⁶,Consoli Agostino⁷,Avogaro Angelo⁸^ORCID,Fadini Gian Paolo^ORCID,

Affiliation:

1. Unit of Biostatistics, Epidemiology and Public Health, Department of CardiacThoracic, Vascular Sciences and Public Health, University of Padova Padova Italy

2. Department of Clinical and Biological SciencesUniversity of Turin Turin Italy

3. Unit of Endocrinology and Metabolic DiseasesFondazione IRCCS Ca’ Granda‐Ospedale Maggiore Policlinico di Milano Milan Italy

4. Unit of Endocrinology, Department of Medical and Surgical SciencesUniversity Hospital of Foggia Foggia Italy

5. Unit of Diabetes Complications, V Clinica Medica, Department of Experimental MedicineUniversity of Rome "La Sapienza" Rome Italy

6. Unit of Diabetology, ASST Bergamo Est Alzano Lombardo Italy

7. Department of Medicine and Aging Science“G. D’Annunzio” University of Chieti Chieti Italy

8. Department of MedicineUniversity of Padova Padova Italy

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13962

Reference32 articles.

1. Impact of FDA‐required cardiovascular outcome trials on type 2 diabetes clinical study initiation from 2008 to 2017;Kieffer CM;Ther Innov Regul Sci.,2019

2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

4. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence to GLP1‐RA and SGLT2‐I affects clinical outcomes and costs in patients with type 2 diabetes;Diabetes/Metabolism Research and Reviews;2024-03-28

2. A systematic review and meta‐analysis of observational studies of the association between the use of incretin‐based therapies and the risk of pancreatic cancer;Pharmacoepidemiology and Drug Safety;2022-12-11

3. Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes;International Journal of Environmental Research and Public Health;2022-11-11

4. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?;Diabetologia;2022-07-29

5. A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study;Advances in Therapy;2022-06-11